Licsandru Erol, Tanc Muhammet, Kocsis Istvan, Barboiu Mihail, Supuran Claudiu T
a Adaptive Supramolecular Nanosystems Group, Institut Europeen des Membranes , University of Montpellier ENSCM-UMR CNRS 5635 , Montpellier , France.
b Department of Neurofarba and Laboratorio di Chimica Bioinorganica, Sezione di Chimica Farmaceutica e Nutraceutica , Università degli Studi di Firenze , Sesto Fiorentino (Florence) , Italy.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):37-46. doi: 10.1080/14756366.2016.1232254. Epub 2016 Nov 1.
A series of ureido and bis-ureido derivatives were prepared by reacting histamine with alkyl/aryl-isocyanates or di-isocyanates. The obtained derivatives were assayed as activators of the enzyme carbonic anhydrase (CA, EC 4.2.1.1), due to the fact that histamine itself has this biological activity. Although inhibition of CAs has pharmacological applications in the field of antiglaucoma, anticonvulsant, anticancer, and anti-infective agents, activation of these enzymes is not yet properly exploited pharmacologically for cognitive enhancement or Alzheimer's disease treatment, conditions in which a diminished CA activity was reported. The ureido/bis-ureido histamine derivatives investigated here showed activating effects only against the cytosolic human (h) isoform hCA I, having no effect on the widespread, physiologically dominant isoform hCA II. This is the first report in which CA I-selective activators were identified. Such compounds may constitute interesting tools for better understanding the physiological/pharmacological effects connected to activation of this widespread CA isoform, whose physiological function is not fully understood.
通过使组胺与烷基/芳基异氰酸酯或二异氰酸酯反应,制备了一系列脲基和双脲基衍生物。由于组胺本身具有这种生物活性,因此对所获得的衍生物作为碳酸酐酶(CA,EC 4.2.1.1)的激活剂进行了测定。尽管抑制碳酸酐酶在抗青光眼、抗惊厥、抗癌和抗感染药物领域具有药理学应用,但这些酶的激活在认知增强或阿尔茨海默病治疗方面尚未得到充分的药理学开发利用,据报道在这些病症中碳酸酐酶活性降低。本文研究的脲基/双脲基组胺衍生物仅对胞质型人(h)同工型hCA I显示出激活作用,对广泛存在的、生理上占主导地位的同工型hCA II没有影响。这是首次鉴定出CA I选择性激活剂的报告。这类化合物可能构成有趣的工具,有助于更好地理解与这种广泛存在的CA同工型激活相关的生理/药理作用,其生理功能尚未完全了解。